SPYRE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
SPYRE THERAPEUTICS, INC. (SYRE) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $2.49 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $2.49M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $1.06M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $116.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $38.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2026-06-30 | $2.49M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $116.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $38.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $153.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $161.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $493.00K 10-K · filed 2026-02-19 |
| 2024-09-30 | $20.00K 10-Q/A · filed 2024-11-18 |
| 2024-06-30 | $673.00K 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $451.00K 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $1.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $115.00K 10-Q · filed 2023-11-09 |
| 2023-03-31 | $1.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $34.00K 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |